Company / R&D per Share
Candel Therapeutics, Inc. R&D per Share History
FY2021-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D per Share
$0.85
FY2023
5-year range
$0.53 / $0.85
FY2021-FY2023
Trend
+60.2%
vs FY2022
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from $0.75 to $0.85 over the past 2 years.
Based on SEC 10-K filings.
0.85 in FY2023.
Improved from $0.75 to $0.85 over the past 2 years.
R&D per Share over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2023, r&d per share increased 60.2% year-over-year.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -5.13 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2023 | $0.85 | +60.2% |
| FY2022 | $0.53 | -29.7% |
| FY2021 | $0.75 | - |
As of FY2023 · SEC 10-K · Updated Jun 24, 2026